2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 452.830 | 487.535 | 484.727 | 529.206 | 585.050 | 612.336 | 746.448 | 793.545 | 945.875 | 1.073.644 |
Total Income - EUR | 452.838 | 487.538 | 487.218 | 531.413 | 590.635 | 613.069 | 750.239 | 796.143 | 955.476 | 1.076.804 |
Total Expenses - EUR | 385.578 | 427.715 | 449.420 | 459.773 | 507.011 | 537.691 | 632.364 | 680.549 | 806.056 | 904.208 |
Gross Profit/Loss - EUR | 67.259 | 59.823 | 37.798 | 71.640 | 83.624 | 75.378 | 117.875 | 115.594 | 149.420 | 172.596 |
Net Profit/Loss - EUR | 56.893 | 51.094 | 32.418 | 64.958 | 77.876 | 70.026 | 112.016 | 109.766 | 141.411 | 154.709 |
Employees | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 |
Check the financial reports for the company - Valifarm Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 47.064 | 56.866 | 50.843 | 42.382 | 52.132 | 44.199 | 39.087 | 58.619 | 57.638 | 49.355 |
Current Assets | 207.610 | 214.318 | 114.280 | 150.828 | 178.579 | 176.223 | 254.783 | 273.204 | 293.471 | 394.838 |
Inventories | 75.863 | 100.078 | 85.945 | 95.932 | 102.019 | 118.322 | 142.636 | 151.424 | 166.371 | 203.569 |
Receivables | 51.638 | 37.710 | 13.681 | 48.382 | 69.982 | 56.203 | 93.887 | 104.976 | 123.804 | 131.973 |
Cash | 80.109 | 76.529 | 14.654 | 6.514 | 6.577 | 1.697 | 18.259 | 16.805 | 3.296 | 59.296 |
Shareholders Funds | 204.852 | 230.874 | 90.669 | 128.192 | 163.652 | 88.757 | 183.857 | 221.857 | 159.435 | 313.661 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 58.187 | 47.491 | 87.126 | 72.115 | 70.001 | 132.231 | 110.013 | 127.682 | 211.717 | 150.197 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Valifarm Srl